

CLAIMS

What is claimed is:

1. A method of treatment, comprising:
 - a) providing:
 - i) a mammal,
 - ii) a therapeutic formulation comprising avian polyclonal antibodies directed to TNF, and;
 - b) administering said formulation to said mammal.
2. The method of Claim 1, wherein said mammal is a human.
3. The method of Claim 1, wherein said administering is performed intravenously.
4. The method of Claim 1, wherein said administering is performed orally.
5. The method of Claim 1, wherein said administering is performed parenterally.
6. The method of Claim 1, wherein said administering is performed rectally.
7. The method of Claim 2, wherein said human has symptoms of inflammatory bowel disease.
8. The method of Claim 2 wherein said human has symptoms of ulcerative colitis
9. The method of Claim 2 wherein said human has symptoms of proctitis.
10. The method of Claim 2 wherein said human has symptoms of Crohn's disease.
11. The method of Claim 1, wherein said formulation is an enteric formulation.

12. The method of Claim 1, wherein said avian antibodies are chicken antibodies.
13. The method of Claim 12, wherein said chicken antibodies are derived from chicken eggs.
14. The method of Claim 1, wherein said formulation further comprises polyclonal antibodies directed to another cytokine.
15. The method of Claim 1, wherein said formulation further comprises polyclonal antibodies directed to IL-6.
16. A method of treatment, comprising:
 - a) providing:
 - i) a human patient with symptoms of inflammatory bowel disease,
 - ii) a therapeutic formulation comprising polyclonal antibodies directed to IL-6, and;
 - b) administering said formulation to said patient.
17. The method of Claim 16, wherein said human is a child.
18. The method of Claim 16, wherein said administering reduces said symptoms.
19. The method of Claim 16, wherein said administering is performed orally.
20. The method of Claim 16, wherein said administering is performed parenterally.
21. The method of Claim 16, wherein said administering is performed rectally.

22. The method of Claim 16, wherein said human has symptoms of ulcerative colitis
23. The method of Claim 16, wherein said human has symptoms of proctitis.
24. The method of Claim 16, wherein said human has symptoms of Crohn's disease.
25. The method of Claim 16, wherein said formulation is an enteric formulation.
26. The method of Claim 16, wherein said polyclonal antibodies are avian antibodies.
27. The method of Claim 26, wherein said avian polyclonal antibodies are chicken antibodies.
28. The method of Claim 27, wherein said chicken antibodies are purified antibodies.
29. The method of Claim 28, wherein said chicken antibodies are purified from chicken eggs.
30. The method of Claim 16, wherein said formulation further comprises polyclonal antibodies directed to another cytokine.
31. The method of Claim 16, wherein said formulation further comprises polyclonal antibodies directed to TNF.

32. A method of treatment, comprising:
- a) providing:
 - i) a human patient with symptoms of Crohn's disease,
 - ii) a therapeutic formulation comprising polyclonal antibodies directed to IL-6, and;
 - b) administering said formulation to said patient.
33. The method of Claim 32, wherein said administering reduces said symptoms.
34. The method of Claim 32, wherein said administering is performed orally.
35. The method of Claim 32, wherein said administering is performed parenterally.
36. The method of Claim 32, wherein said administering is performed rectally.
37. The method of Claim 32, wherein said human has symptoms of ulcerative colitis
38. The method of Claim 32, wherein said human has symptoms of proctitis.
39. The method of Claim 32, wherein said human has symptoms of Crohn's disease.
40. The method of Claim 32, wherein said formulation is an enteric formulation.
41. The method of Claim 32, wherein said polyclonal antibodies are avian antibodies.

42. The method of Claim 41, wherein said avian polyclonal antibodies are chicken antibodies.
43. The method of Claim 42, wherein said chicken antibodies are purified antibodies.
44. The method of Claim 43, wherein said chicken antibodies are purified from chicken eggs.
45. A method of treatment, comprising:
- a) providing:
 - i) a human patient with symptoms of inflammatory bowel disease,
 - ii) a therapeutic formulation comprising polyclonal antibodies directed to a first cytokine and a second cytokine, and;
 - b) administering said formulation to said patient.
46. The method of Claim 45, wherein said first cytokine is TNF alpha.
47. The method of Claim 46, wherein said second cytokine is IL-6.
48. The method of Claim 45, wherein said administering reduces said symptoms.
49. The method of Claim 45, wherein said administering is performed orally.
50. The method of Claim 45, wherein said administering is performed parenterally.
51. The method of Claim 45, wherein said administering is performed rectally.
52. The method of Claim 45, wherein said human has symptoms of ulcerative colitis

- 53. The method of Claim 45, wherein said human has symptoms of proctitis.
- 54. The method of Claim 45, wherein said human has symptoms of Crohn's disease.
- 55. The method of Claim 45, wherein said formulation is an enteric formulation.
- 56. The method of Claim 45, wherein said polyclonal antibodies are avian antibodies.
- 57. The method of Claim 56, wherein said avian polyclonal antibodies are chicken antibodies.
- 58. The method of Claim 57, wherein said chicken antibodies are purified from chicken eggs.